Wealth Enhancement Advisory Services LLC Has $12.53 Million Stock Holdings in Edwards Lifesciences Corporation $EW

Key Points

• Wealth Enhancement Advisory Services LLC increased its stake in Edwards Lifesciences Corporation by 111.9%, owning a total of 163,202 shares valued at $12,532,000 after purchasing an additional 86,186 shares during the second quarter.
• Analyst ratings for Edwards Lifesciences show a consensus of "Moderate Buy" with a target price around $87.17, reflecting a range of recent upgrades and assessments.
• Edwards Lifesciences reported a net margin of 72.96% and a revenue increase of 11.9% year-over-year, beating analyst estimates for both earnings per share and revenue in its latest quarterly results.

Wealth Enhancement Advisory Services LLC grew its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 111.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 163,202 shares of the medical research company's stock after purchasing an additional 86,186 shares during the period. Wealth Enhancement Advisory Services LLC's holdings in Edwards Lifesciences were worth $12,532,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Wedmont Private Capital grew its stake in Edwards Lifesciences by 22.6% during the second quarter. Wedmont Private Capital now owns 12,090 shares of the medical research company's stock worth $933,000 after buying an additional 2,230 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd raised its position in Edwards Lifesciences by 2.1% in the second quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 73,781 shares of the medical research company's stock valued at $5,770,000 after purchasing an additional 1,521 shares during the period. Radnor Capital Management LLC boosted its position in shares of Edwards Lifesciences by 12.5% in the second quarter. Radnor Capital Management LLC now owns 27,090 shares of the medical research company's stock worth $2,119,000 after buying an additional 3,020 shares during the period. Pallas Capital Advisors LLC raised its holdings in shares of Edwards Lifesciences by 28.8% during the 2nd quarter. Pallas Capital Advisors LLC now owns 3,952 shares of the medical research company's stock valued at $309,000 after buying an additional 884 shares during the period. Finally, Aaron Wealth Advisors LLC lifted its position in Edwards Lifesciences by 6.9% during the 2nd quarter. Aaron Wealth Advisors LLC now owns 6,003 shares of the medical research company's stock worth $469,000 after acquiring an additional 390 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Royal Bank Of Canada lifted their price objective on shares of Edwards Lifesciences from $85.00 to $89.00 and gave the company an "outperform" rating in a research note on Friday, July 25th. Barclays lifted their price target on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock an "overweight" rating in a research note on Friday, July 25th. Morgan Stanley raised their target price on Edwards Lifesciences from $75.00 to $81.00 and gave the company an "equal weight" rating in a research note on Tuesday, July 15th. William Blair upgraded Edwards Lifesciences to a "strong-buy" rating in a research note on Friday, July 25th. Finally, Truist Financial increased their price target on Edwards Lifesciences from $81.00 to $82.00 and gave the company a "hold" rating in a report on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Edwards Lifesciences currently has an average rating of "Moderate Buy" and a consensus target price of $86.61.

Insider Activity

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of the company's stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the sale, the vice president directly owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. This represents a 15.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the transaction, the insider directly owned 206,900 shares in the company, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.34% of the company's stock.

Edwards Lifesciences Stock Performance

NYSE:EW traded down $0.61 during mid-day trading on Monday, hitting $73.80. The stock had a trading volume of 3,669,508 shares, compared to its average volume of 4,054,987. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The company has a 50 day simple moving average of $78.69 and a 200-day simple moving average of $75.56. The stock has a market capitalization of $43.33 billion, a price-to-earnings ratio of 10.62, a P/E/G ratio of 3.59 and a beta of 1.07. Edwards Lifesciences Corporation has a 52 week low of $64.00 and a 52 week high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same period in the prior year, the company posted $0.70 EPS. The business's revenue for the quarter was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, research analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.